Capecitabine plus bevacizumab (Cape-Bev) as a maintenance treatment after induction treatment with FOLFIRI plus bevacizumab (FOLFIRI-Bev) in metastatic colorectal cancer (mCRC).


Tatli A. M., COŞKUN H. Ş., Uysal M., SEZGİN GÖKSU S., Arslan D., Gunduz S., ...More

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text) identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 31
  • City: Illinois
  • Country: United States Of America
  • Akdeniz University Affiliated: Yes